n/a
Abstract Title:

N-Acetyl Cysteine Is Associated With Dopaminergic Improvement in Parkinson's Disease.

Abstract Source:

Clin Pharmacol Ther. 2019 Oct ;106(4):884-890. Epub 2019 Jul 17. PMID: 31206613

Abstract Author(s):

Daniel A Monti, George Zabrecky, Daniel Kremens, Tsao-Wei Liang, Nancy A Wintering, Anthony J Bazzan, Li Zhong, Brendan K Bowens, Inna Chervoneva, Charles Intenzo, Andrew B Newberg

Article Affiliation:

Daniel A Monti

Abstract:

This study assessed the biological and clinical effects in patients with Parkinson's disease (PD) of N-acetyl-cysteine (NAC), the prodrug to l-cysteine, a precursor to the natural biological antioxidant glutathione. Forty-two patients with PD were randomized to either weekly intravenous infusions of NAC (50 mg/kg) plus oral doses (500 mg twice per day) for 3 months or standard of care only. Participants received prebrain and postbrain imaging with ioflupane (DaTscan) to measure dopamine transporter (DAT) binding. In the NAC group, significantly increased DAT binding was found in the caudate and putamen (mean increase from 3.4% to 8.3%) compared with controls (P < 0.05), along with significantly improved PD symptoms (P < 0.0001). The results suggest NAC may positively affect the dopaminergic system in patients with PD, with corresponding positive clinical effects. Larger scale studies are warranted.

Study Type : Human Study

Print Options


Key Research Topics

This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2024 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.